Matches in SemOpenAlex for { <https://semopenalex.org/work/W4252002392> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W4252002392 endingPage "iii19" @default.
- W4252002392 startingPage "iii18" @default.
- W4252002392 abstract "Brain cancers are the leading cause of cancer related mortality and morbidity in children and young adults. Children with diffuse intrinsic brainstem malignant gliomas have one-year progression-free survival rates below 25% and median overall survival of 9 to 10 months with current treatment options and hence represent a significant unmet medical need. Genome-wide sequencing efforts of pediatric gliomas have identified a recurrent and shared missense mutation in the gene encoding the replication-independent variant of histone 3, H3.3. Approximately 70% of diffuse intrinsic pontine gliomas (DIPG) and 50% of thalamic and other midline gliomas harbor the amino-acid substitution from lysine (K) to methionine (M) at the position 27 of H3.3 gene (H3.3.K27M mutation). Tumor-specific missense mutations are not subjected to self-tolerance and can be suitable targets (i.e. neoantigen) for cancer immunotherapy. We evaluated whether the H3.3.K27M mutation can induce specific cytotoxic T lymphocyte (CTL) response in HLA-A2+ human T cells. In vitro stimulation of HLA-A2+ donor-derived CD8+ T-cells with a synthetic peptide encompassing the H3.3.K27M mutation (H3.3.K27M epitope) induced CTL lines which recognized not only T2 cells loaded with the synthetic H3.3.K27M epitope peptide but also lysed HLA-A2+ DIPG cell lines which endogenously harbor the H3.3.K27M mutation. On the other hand, the CTL lines did not react to either HLA-A2+ H3.3.K27M -negative DIPG cell lines or H3.3K27M-positive but HLA-A2-negative cells. The H3.3.K27M epitope peptide, but not the non-mutant counterpart, indicated an excellent affinity (Kd 151nM) to HLA-A2 based on competitive binding inhibition assay. From CTL clones with high and specific affinities to HLA-A2-H3.3.K27M-tetramer, cDNAs for T cell receptor (TCR) α- and β-chains were cloned into a retroviral vector. Human HLA-A2+ T-cells transduced with the TCR demonstrated antigen-specific reactivity as well as anti-glioma responses in vitro. Peptide titration assay suggested that the H3.3.K27M-specific TCR had the half-maximal reactivity for peptide recognition of around 100nM. Furthermore, critically important for safety of clinical application, alanine scanning demonstrated that the key amino-acid sequence motif in the epitope for the TCR reactivity is not shared by any known human protein. Finally, intravenous administration of T-cells transduced with the H3.3.K27M-specific TCR significantly inhibited the growth of intracranial HLA-A2+ H3.3.K27M-positive glioma xenografts in immune-deficient mice. These data provide us with a strong basis for developing peptide-based vaccines as well as adoptive transfer therapy using autologous T-cells transduced with the H3.3.K27M-specific TCR." @default.
- W4252002392 created "2022-05-12" @default.
- W4252002392 creator A5010966529 @default.
- W4252002392 creator A5022169733 @default.
- W4252002392 creator A5037285448 @default.
- W4252002392 creator A5045031619 @default.
- W4252002392 creator A5048874956 @default.
- W4252002392 creator A5050145067 @default.
- W4252002392 creator A5058793243 @default.
- W4252002392 creator A5085277907 @default.
- W4252002392 creator A5086986431 @default.
- W4252002392 date "2017-04-01" @default.
- W4252002392 modified "2023-09-27" @default.
- W4252002392 title "OS09.4 Identification of a novel H3.3.K27M mutation-derived neoantigen epitope and cloning of H3.3.K27M-specific T-cell receptor for T-cell therapy in gliomas" @default.
- W4252002392 doi "https://doi.org/10.1093/neuonc/nox036.063" @default.
- W4252002392 hasPublicationYear "2017" @default.
- W4252002392 type Work @default.
- W4252002392 citedByCount "0" @default.
- W4252002392 crossrefType "journal-article" @default.
- W4252002392 hasAuthorship W4252002392A5010966529 @default.
- W4252002392 hasAuthorship W4252002392A5022169733 @default.
- W4252002392 hasAuthorship W4252002392A5037285448 @default.
- W4252002392 hasAuthorship W4252002392A5045031619 @default.
- W4252002392 hasAuthorship W4252002392A5048874956 @default.
- W4252002392 hasAuthorship W4252002392A5050145067 @default.
- W4252002392 hasAuthorship W4252002392A5058793243 @default.
- W4252002392 hasAuthorship W4252002392A5085277907 @default.
- W4252002392 hasAuthorship W4252002392A5086986431 @default.
- W4252002392 hasBestOaLocation W42520023921 @default.
- W4252002392 hasConcept C104317684 @default.
- W4252002392 hasConcept C121608353 @default.
- W4252002392 hasConcept C147483822 @default.
- W4252002392 hasConcept C147969180 @default.
- W4252002392 hasConcept C154317977 @default.
- W4252002392 hasConcept C167672396 @default.
- W4252002392 hasConcept C195616568 @default.
- W4252002392 hasConcept C202751555 @default.
- W4252002392 hasConcept C203014093 @default.
- W4252002392 hasConcept C2776745794 @default.
- W4252002392 hasConcept C2777701055 @default.
- W4252002392 hasConcept C501734568 @default.
- W4252002392 hasConcept C502942594 @default.
- W4252002392 hasConcept C54355233 @default.
- W4252002392 hasConcept C64927066 @default.
- W4252002392 hasConcept C75563809 @default.
- W4252002392 hasConcept C86803240 @default.
- W4252002392 hasConceptScore W4252002392C104317684 @default.
- W4252002392 hasConceptScore W4252002392C121608353 @default.
- W4252002392 hasConceptScore W4252002392C147483822 @default.
- W4252002392 hasConceptScore W4252002392C147969180 @default.
- W4252002392 hasConceptScore W4252002392C154317977 @default.
- W4252002392 hasConceptScore W4252002392C167672396 @default.
- W4252002392 hasConceptScore W4252002392C195616568 @default.
- W4252002392 hasConceptScore W4252002392C202751555 @default.
- W4252002392 hasConceptScore W4252002392C203014093 @default.
- W4252002392 hasConceptScore W4252002392C2776745794 @default.
- W4252002392 hasConceptScore W4252002392C2777701055 @default.
- W4252002392 hasConceptScore W4252002392C501734568 @default.
- W4252002392 hasConceptScore W4252002392C502942594 @default.
- W4252002392 hasConceptScore W4252002392C54355233 @default.
- W4252002392 hasConceptScore W4252002392C64927066 @default.
- W4252002392 hasConceptScore W4252002392C75563809 @default.
- W4252002392 hasConceptScore W4252002392C86803240 @default.
- W4252002392 hasIssue "suppl_3" @default.
- W4252002392 hasLocation W42520023921 @default.
- W4252002392 hasLocation W42520023922 @default.
- W4252002392 hasLocation W42520023923 @default.
- W4252002392 hasOpenAccess W4252002392 @default.
- W4252002392 hasPrimaryLocation W42520023921 @default.
- W4252002392 hasRelatedWork W1980416103 @default.
- W4252002392 hasRelatedWork W1988201115 @default.
- W4252002392 hasRelatedWork W2018916009 @default.
- W4252002392 hasRelatedWork W2024196340 @default.
- W4252002392 hasRelatedWork W2040554954 @default.
- W4252002392 hasRelatedWork W2053177727 @default.
- W4252002392 hasRelatedWork W2054101033 @default.
- W4252002392 hasRelatedWork W2119517715 @default.
- W4252002392 hasRelatedWork W2120320343 @default.
- W4252002392 hasRelatedWork W2194100344 @default.
- W4252002392 hasVolume "19" @default.
- W4252002392 isParatext "false" @default.
- W4252002392 isRetracted "false" @default.
- W4252002392 workType "article" @default.